Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Immune Checkpoint Modulators: An Emerging Antiglioma Armamentarium JOURNAL OF IMMUNOLOGY RESEARCH Kim, E. S., Kim, J. E., Patel, M. A., Mangraviti, A., Ruzevick, J., Lim, M. 2016; 2016: 4683607

Abstract

Immune checkpoints have come to the forefront of cancer therapies as a powerful and promising strategy to stimulate antitumor T cell activity. Results from recent preclinical and clinical studies demonstrate how checkpoint inhibition can be utilized to prevent tumor immune evasion and both local and systemic immune suppression. This review encompasses the key immune checkpoints that have been found to play a role in tumorigenesis and, more specifically, gliomagenesis. The review will provide an overview of the existing preclinical and clinical data, antitumor efficacy, and clinical applications for each checkpoint with respect to GBM, as well as a summary of combination therapies with chemotherapy and radiation.

View details for DOI 10.1155/2016/4683607

View details for Web of Science ID 000368461900001

View details for PubMedID 26881264

View details for PubMedCentralID PMC4736366